Neuroendocrine tumours: Cracking the epigenetic code

Endocrine-Related Cancer

Volumn 20, Issue 3, 2013, Pages

  Karpathakis, A ^a,b   Dibra, H ^a   Thirlwell, C ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

ATRX DAXX; Carcinoid; Epigenetic; Histone; Methylation; MiRNA; Neuroendocrine; RASSF1

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; MICRORNA;

ADENOCARCINOMA; ADRENAL CORTEX TUMOR; BRONCHIAL NEUROENDOCRINE TUMOR; CANCER GRADING; CANCER PROGNOSIS; CPG ISLAND; DNA METHYLATION; EPIGENETICS; GASTROINTESTINAL NEUROENDOCRINE TUMOR; HISTONE MODIFICATION; HUMAN; INSULINOMA; MERKEL CELL TUMOR; NEUROENDOCRINE TUMOR; PANCREATIC NEUROENDOCRINE TUMOR; PHEOCHROMOCYTOMA; PROTEIN EXPRESSION; REVIEW;

ATRX/DAXX; CARCINOID; EPIGENETIC, METHYLATION; HISTONE; MIRNA; NEUROENDOCRINE; RASSF1;

CHROMATIN; DNA METHYLATION; EPIGENESIS, GENETIC; GASTROINTESTINAL NEOPLASMS; HUMANS; LUNG NEOPLASMS; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS;

EID: 84879477036     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-12-0338     Document Type: Review

References (142)

1. Adler JT, Hottinger DG, Kunnimalaiyaan M & Chen H 2009 Combination therapy with histone deacetylase inhibitors and lithium chloride: a novel treatment for carcinoid tumors. Annals of Surgical Oncology 16 481-486. (doi:10.1245/s10434-008-0194-6)
2. Agarwal SK, Guru SC, Heppner C, Erdos MR, Collins RM, Park SY, Saggar S, Chandrasekharappa SC, Collins FS, Spiegel AM et al. 1999 Menin interacts with the AP1 transcription factor JunD and represses JunD-activated transcription. Cell 96 143-152. (doi:10.1016/S0092-8674(00)80967-8)
3. Alexander VM, Roy M, Steffens KA, Kunnimalaiyaan M & Chen H 2010 Azacytidine induces cell cycle arrest and suppression of neuroendocrine markers in carcinoids. International Journal of Clinical and Experimental Medicine 3 95-102.
4. Allfrey VG, Faulkner R & Mirsky AE 1964 Acetylation and methylation of histones and their possible role in the regulation of RNA synthesis. PNAS 51 786-794. (doi:10.1073/pnas.51.5.786)
5. Arnold CN, Sosnowski A, Schmitt-Graff A, Arnold R & Blum HE 2007 Analysis of molecular pathways in sporadic neuroendocrine tumors of the gastro-entero-pancreatic system. International Journal of Cancer 120 2157-2164. (doi:10.1002/ijc.22569)
6. Arnold CN, Nagasaka T, Goel A, Scharf I, Grabowski P, Sosnowski A, Schmitt-Graff A, Boland CR, Arnold R & Blum HE 2008 Molecular characteristics and predictors of survival in patients with malignant neuroendocrine tumors. International Journal of Cancer 123 1556-1564. (doi:10.1002/ijc.23690)
7. Astuti D, Latif F, Wagner K, Gentle D, Cooper WN, Catchpoole D, Grundy R, Ferguson-Smith AC & Maher ER 2005 Epigenetic alteration at the DLK1-GTL2 imprinted domain in human neoplasia: analysis of neuroblastoma, phaeochromocytoma and Wilms' tumour. British Journal of Cancer 92 1574-1580. (doi:10.1038/sj.bjc.6602478)
8. Bachmann IM, Halvorsen OJ, Collett K, Stefansson IM, Straume O, Haukaas SA, Salvesen HB, Otte AP & Akslen LA 2006 EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. Journal of Clinical Oncology 24 268-273. (doi:10.1200/JCO.2005. 01.5180)
9. Baradari V, Huether A, Hopfner M, Schuppan D & Scherubl H 2006 Antiproliferative and proapoptotic effects of histone deacetylase inhibitors on gastrointestinal neuroendocrine tumor cells. Endocrine-Related Cancer 13 1237-1250. (doi:10.1677/erc.1.01249)
10. Barghorn A, Komminoth P, Bachmann D, Rutimann K, Saremaslani P, Muletta-Feurer S, Perren A, Roth J, Heitz PU & Speel EJ 2001 Deletion at 3p25.3-p23 is frequently encountered in endocrine pancreatic tumours and is associated with metastatic progression. Journal of Pathology 194 451-458. (doi:10.1002/path.886)
11. Barlesi F, Giaccone G, Gallegos-Ruiz MI, Loundou A, Span SW, Lefesvre P, Kruyt FA & Rodriguez JA 2007 Global histone modifications predict prognosis of resected non small-cell lung cancer. Journal of Clinical Oncology 25 4358-4364. (doi:10.1200/JCO.2007.11.2599)
12. Barreau O, Assie G, Wilmot-Roussel H, Ragazzon B, Baudry C, Perlemoine K, Rene-Corail F, Bertagna X, Dousset B, Hamzaoui N et al. 2013 Identification of a CpG island methylator phenotype in adrenocortical carcinomas. Journal of Clinical Endocrinology and Metabolism 98 E174-E184. (doi:10.1210/jc.2012-2993)
13. Bartsch DK, Kersting M, Wild A, Ramaswamy A, Gerdes B, Schuermann M, Simon B & Rothmund M 2000 Low frequency of p16(INK4a) alterations in insulinomas. Digestion 62 171-177. (doi:10.1159/000007810)
14. Bauer W, Briner U, Doepfner W, Haller R, Huguenin R, Marbach P, Petcher TJ & Pless 1982 SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sciences 31 1133-1140. (doi:10.1016/0024-3205(82)90087-X)
15. Bernstein BE, Stamatoyannopoulos JA, Costello JF, Ren B, Milosavljevic A, Meissner A, Kellis M, Marra MA, Beaudet AL, Ecker JR et al. 2010 The NIH roadmap epigenomics mapping consortium. Nature Biotechnology 28 1045-1048. (doi:10.1038/nbt1010-1045)
16. Bestor TH 1992 Activation of mammalian DNA methyltransferase by cleavage of a Zn binding regulatory domain. EMBO Journal 11 2611-2617.
17. Bruns C, Lewis I, Briner U, Meno-Tetang G & Weckbecker G 2002 SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. European Journal of Endocrinology/European Federation of Endocrine Societies 146 707-716. (doi:10.1530/eje.0.1460707)
18. Cairns P, Esteller M, Herman JG, Schoenberg M, Jeronimo C, Sanchez-Cespedes M, Chow NH, Grasso M, Wu L, Westra WB et al. 2001 Molecular detection of prostate cancer in urine by GSTP1 hypermethylation. Clinical Cancer Research 7 2727-2730.
19. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M et al. 2004 Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. PNAS 101 2999-3004. (doi:10.1073/pnas. 0307323101)
20. Cascon A, Ruiz-Llorente S, Fraga MF, Leton R, Telleria D, Sastre J, Diez JJ, Martinez Diaz-Guerra G, Diaz Perez JA, Benitez J et al. 2004 Genetic and epigenetic profile of sporadic pheochromocytomas. Journal of Medical Genetics 41 e30. (doi:10.1136/jmg.2003.012658)
21. Catteau A, Harris WH, Xu CF & Solomon E 1999 Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics. Oncogene 18 1957-1965. (doi:10.1038/sj.onc. 1202509)
22. Chadwick LH 2012 The NIH Roadmap Epigenomics Program data resource. Epigenomics 4 317-324. (doi:10.2217/epi.12.18)
23. Chan AO, Kim SG, Bedeir A, Issa JP, Hamilton SR & Rashid A 2003 CpG island methylation in carcinoid and pancreatic endocrine tumors. Oncogene 22 924-934. (doi:10.1038/sj.onc.1206123)
24. Chaussade L, Eymin B, Brambilla E & Gazzeri S 2001 Expression of p15 and p15.5 products in neuroendocrine lung tumours: relationship with p15(INK4b) methylation status. Oncogene 20 6587-6596. (doi:10.1038/sj.onc.1204798)
25. Chi AS & Bernstein BE 2009 Developmental biology. Pluripotent chromatin state. Science 323 220-221. (doi:10.1126/science.1166261)
26. Choi IS, Estecio MR, Nagano Y, Kim do H, White JA, Yao JC, Issa JP & Rashid A 2007 Hypomethylation of LINE-1 and Alu in well-differentiated neuroendocrine tumors (pancreatic endocrine tumors and carcinoid tumors). Modern Pathology 20 802-810. (doi:10.1038/modpathol.3800825)
27. Chung DC, Smith AP, Louis DN, Graeme-Cook F, Warshaw AL & Arnold A 1997a Analysis of the retinoblastoma tumour suppressor gene in pancreatic endocrine tumours. Clinical Endocrinology 47 523-528. (doi:10.1046/j.1365-2265. 1997.2861110.x)
28. Chung DC, Smith AP, Louis DN, Graeme-Cook F, Warshaw AL & Arnold A 1997b A novel pancreatic endocrine tumor suppressor gene locus on chromosome 3p with clinical prognostic implications. Journal of Clinical Investigation 100 404-410. (doi:10.1172/JCI119547)
29. Clark SJ, Harrison J, Paul CL & Frommer M 1994 High sensitivity mapping of methylated cytosines. Nucleic Acids Research 22 2990-2997. (doi:10.1093/nar/22.15.2990)
30. Dammann R, Li C, Yoon JH, Chin PL, Bates S & Pfeifer GP 2000 Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nature Genetics 25 315-319. (doi:10.1038/77083)
31. Dammann R, Schagdarsurengin U, Liu L, Otto N, Gimm O, Dralle H, Boehm BO, Pfeifer GP & Hoang-Vu C 2003a Frequent RASSF1A promoter hypermethylation and K-ras mutations in pancreatic carcinoma. Oncogene 22 3806-3812. (doi:10.1038/sj.onc.1206582)
32. Dammann R, Schagdarsurengin U, Strunnikova M, Rastetter M, Seidel C, Liu L, Tommasi S & Pfeifer GP 2003b Epigenetic inactivation of the Rasassociation domain family 1 (RASSF1A) gene and its function in human carcinogenesis. Histology and Histopathology 18 665-677.
33. Dejeux E, Olaso R, Dousset B, Audebourg A, Gut IG, Terris B & Tost J 2009 Hypermethylation of the IGF2 differentially methylated region 2 is a specific event in insulinomas leading to loss-of-imprinting and overexpression. Endocrine-Related Cancer 16 939-952. (doi:10.1677/ERC-08-0331)
34. Eckhardt F, Beck S, Gut IG & Berlin K 2004 Future potential of the Human Epigenome Project. Expert Review of Molecular Diagnostics 4 609-618. (doi:10.1586/14737159.4.5.609)
35. Eden A, Gaudet F, Waghmare A & Jaenisch R 2003 Chromosomal instability and tumors promoted by DNA hypomethylation. Science 300 455. (doi:10.1126/science.1083557)
36. Estrabaud E, Lassot I, Blot G, Le Rouzic E, Tanchou V, Quemeneur E, Daviet L, Margottin-Goguet F & Benarous R 2007 RASSF1C, an isoform of the tumor suppressor RASSF1A, promotes the accumulation of β-catenin by interacting with bTrCP. Cancer Research 67 1054-1061. (doi:10.1158/0008-5472. CAN-06-2530)
37. Feil R & Fraga MF 2011 Epigenetics and the environment: emerging patterns and implications. Nature Reviews. Genetics 13 97-109.
38. Feinberg AP & Vogelstein B 1983 Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 301 89-92. (doi:10.1038/301089a0)
39. Findeis-Hosey JJ, Huang J, Li F, Yang Q, McMahon LA & Xu H 2011 Highgrade neuroendocrine carcinomas of the lung highly express enhancer of zeste homolog 2, but carcinoids do not. Human Pathology 42 867-872. (doi:10.1016/j.humpath.2010.09.019)
40. Fonseca AL, Kugelberg J, Starker LF, Scholl U, Choi M, Hellman P, Akerstrom G, Westin G, Lifton RP, Bjorklund P et al. 2012 Comprehensive DNA methylation analysis of benign and malignant adrenocortical tumors. Genes, Chromosomes & Cancer 51 949-960. (doi:10.1002/gcc.21978)
41. Fontaniere S, Tost J, Wierinckx A, Lachuer J, Lu J, Hussein N, Busato F, Gut I, Wang ZQ & Zhang CX 2006 Gene expression profiling in insulinomas of Men1 b-cell mutant mice reveals early genetic and epigenetic events involved in pancreatic b-cell tumorigenesis. Endocrine-Related Cancer 13 1223-1236. (doi:10.1677/erc.1.01294)
42. Fraga MF, Herranz M, Espada J, Ballestar E, Paz MF, Ropero S, Erkek E, Bozdogan O, Peinado H, Niveleau A et al. 2004 A mouse skin multistage carcinogenesis model reflects the aberrant DNA methylation patterns of human tumors. Cancer Research 64 5527-5534. (doi:10.1158/0008-5472.CAN-03-4061)
43. Fraga MF, Ballestar E, Villar-Garea A, Boix-Chornet M, Espada J, Schotta G, Bonaldi T, Haydon C, Ropero S, Petrie K et al. 2005 Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nature Genetics 37 391-400. (doi:10.1038/ng1531)
44. Friedman OM, Mahapatra GN & Stevenson R 1963 The methylation of deoxyribonucleosides by diazomethane. Biochimica et Biophysica Acta 68 144-146. (doi:10.1016/0926-6550(63)90422-5)
45. Frolich JC, Bloomgarden ZT, Oates JA, McGuigan JE & Rabinowitz D 1978 The carcinoid flush. Provocation by pentagastrin and inhibition by somatostatin. New England Journal of Medicine 299 1055-1057. (doi:10.1056/NEJM197811092991908)
46. Fu S, Hu W, Iyer R, Kavanagh JJ, Coleman RL, Levenback CF, Sood AK, Wolf JK, Gershenson DM, Markman M et al. 2011 Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinumrefractory epithelial ovarian cancer. Cancer 117 1661-1669. (doi:10.1002/cncr.25701)
47. Geli J, Kiss N, Karimi M, Lee JJ, Backdahl M, Ekstrom TJ & Larsson C 2008 Global and regional CpG methylation in pheochromocytomas and abdominal paragangliomas: association tomalignant behavior. Clinical Cancer Research 14 2551-2559. (doi:10.1158/1078-0432.CCR-07-1867)
48. Greenblatt DY, Vaccaro AM, Jaskula-Sztul R, Ning L, Haymart M, Kunnimalaiyaan M & Chen H 2007 Valproic acid activates notch-1 signaling and regulates the neuroendocrine phenotype in carcinoid cancer cells. Oncologist 12 942-951. (doi:10.1634/theoncologist. 12-8-942)
49. Greger V, Passarge E, Hopping W, Messmer E & Horsthemke B 1989 Epigenetic changes may contribute to the formation and spontaneous regression of retinoblastoma. Human Genetics 83 155-158. (doi:10.1007/BF00286709)
50. Habbe N, Bert T & Simon B 2007 Identification of methylation- associated gene expression in neuroendocrine pancreatic tumor cells. Pancreatology 7 352-359. (doi:10.1159/000107270)
51. Hamfjord J, Stangeland AM, Hughes T, Skrede ML, Tveit KM, Ikdahl T & Kure EH 2012 Differential expression of miRNAs in colorectal cancer: comparison of paired tumor tissue and adjacent normal mucosa using high-throughput sequencing. PLoS ONE 7 e34150. (doi:10.1371/journal.pone.0034150)
52. Heaphy CM, de Wilde RF, Jiao Y, Klein AP, Edil BH, Shi C, Bettegowda C, Rodriguez FJ, Eberhart CG, Hebbar S et al. 2011a Altered telomeres in tumors with ATRX and DAXX mutations. Science 333 425. (doi:10.1126/science.1207313)
53. Heaphy CM, Subhawong AP, Hong SM, Goggins MG, Montgomery EA, Gabrielson E, Netto GJ, Epstein JI, Lotan TL, Westra WH et al. 2011b Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes. American Journal of Pathology 179 1608-1615. (doi:10.1016/j.ajpath.2011.06.018)
54. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L et al. 2005 MGMT gene silencing and benefit from temozolomide in glioblastoma. New England Journal of Medicine 352 997-1003. (doi:10.1056/NEJMoa043331)
55. Helmbold P, Lahtz C, Enk A, Herrmann-Trost P, Marsch W, Kutzner H & Dammann RH 2009 Frequent occurrence of RASSF1A promoter hypermethylation and Merkel cell polyomavirus in Merkel cell carcinoma. Molecular Carcinogenesis 48 903-909. (doi:10.1002/mc.20540)
56. Herman JG, Latif F, Weng Y, Lerman MI, Zbar B, Liu S, Samid D, Duan DS, Gnarra JR, Linehan WM et al. 1994 Silencing of the VHL tumorsuppressor gene by DNA methylation in renal carcinoma. PNAS 91 9700-9704. (doi:10.1073/pnas.91.21. 9700)
57. Herman JG, Merlo A, Mao L, Lapidus RG, Issa JP, Davidson NE, Sidransky D & Baylin SB 1995 Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Research 55 4525-4530.
58. House MG, Herman JG, Guo MZ, Hooker CM, Schulick RD, Lillemoe KD, Cameron JL, Hruban RH, Maitra A & Yeo CJ 2003 Aberrant hypermethylation of tumor suppressor genes in pancreatic endocrine neoplasms. Annals of Surgery 238 423-431 (discussion 431-422).
59. Jenuwein T & Allis CD 2001 Translating the histone code. Science 293 1074-1080. (doi:10.1126/science.1063127)
60. Jiao Y, Shi C, Edil BH, de Wilde RF, Klimstra DS, Maitra A, Schulick RD, Tang LH, Wolfgang CL, Choti MA et al. 2011 DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 331 1199-1203. (doi:10.1126/science.1200609)
61. Jones PA & Baylin SB 2002 The fundamental role of epigenetic events in cancer. Nature Reviews. Genetics 3 415-428. (doi:10.1038/nrg962)
62. Jones PA & Martienssen R 2005 A blueprint for a Human Epigenome Project: the AACR Human Epigenome Workshop. Cancer Research 65 11241-11246. (doi:10.1158/0008-5472.CAN-05-3865)
63. Kaminskas E, Farrell A, Abraham S, Baird A, Hsieh LS, Lee SL, Leighton JK, Patel H, Rahman A, Sridhara R et al. 2005 Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes. Clinical Cancer Research 11 3604-3608. (doi:10.1158/1078-0432.CCR-04-2135)
64. Kiss NB, Geli J, Lundberg F, Avci C, Velazquez-Fernandez D, Hashemi J, Weber G, Hoog A, Ekstrom TJ, Backdahl M et al. 2008 Methylation of the p16INK4A promoter is associated with malignant behavior in abdominal extra-adrenal paragangliomas but not pheochromocytomas. Endocrine-Related Cancer 15 609-621. (doi:10.1677/ERC-07-0285)
65. Kiss NB, Muth A, Andreasson A, Juhlin CC, Geli J, Backdahl M, Hoog A, Wangberg B, Nilsson O, Ahlman H et al. 2013 Acquired hypermethylation of the P16INK4A promoter in abdominal paraganglioma: relation to adverse tumor phenotype and predisposing mutation. Endocrine-Related Cancer 20 65-78. (doi:10.1530/ERC-12-0267)
66. Krenning EP, Bakker WH, Breeman WA, Koper JW, Kooij PP, Ausema L, Lameris JS, Reubi JC & Lamberts SW 1989 Localisation of endocrinerelated tumours with radioiodinated analogue of somatostatin. Lancet 1 242-244. (doi:10.1016/S0140-6736(89)91258-0)
67. Krenning EP, de Jong M, Kooij PP, Breeman WA, Bakker WH, de Herder WW, van Eijck CH, Kwekkeboom DJ, Jamar F, Pauwels S et al. 1999 Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy. Annals of Oncology 10 (Suppl 2) S23-S29. (doi:10.1093/annonc/10.suppl- 2.S23)
68. Kunnimalaiyaan M, Vaccaro AM, Ndiaye MA & Chen H 2006 Overexpression of the NOTCH1 intracellular domain inhibits cell proliferation and alters the neuroendocrine phenotype of medullary thyroid cancer cells. Journal of Biological Chemistry 281 39819-39830. (doi:10.1074/jbc.M603578200)
69. Lagos-Quintana M, Rauhut R, Lendeckel W & Tuschl T 2001 Identification of novel genes coding for small expressed RNAs. Science 294 853-858. (doi:10.1126/science.1064921)
70. LaRosa S, Marando A, Furlan D, Sahnane N & Capella C 2012 Colorectal poorly differentiated neuroendocrine carcinomas and mixed adenoneuroendocrine carcinomas: insights into the diagnostic immunophenotype, assessment of methylation profile, and search for prognostic markers. American Journal of Surgical Pathology 36 601-611. (doi:10.1097/PAS.0b013e318242e21c)
71. Lassacher A, Heitzer E, Kerl H & Wolf P 2008 p14ARF hypermethylation is common but INK4a-ARF locus or p53 mutations are rare in Merkel cell carcinoma. Journal of Investigative Dermatology 128 1788-1796. (doi:10.1038/sj.jid.5701256)
72. Lee S, Paulson KG, Murchison EP, Afanasiev OK, Alkan C, Leonard JH, Byrd DR, Hannon GJ & Nghiem P 2011 Identification and validation of a novel mature microRNA encoded by the Merkel cell polyomavirus in human Merkel cell carcinomas. Journal of Clinical Virology 52 272-275. (doi:10.1016/j.jcv.2011.08. 012)
73. Lee HW, Lee EH, Ha SY, Lee CH, Chang HK, Chang S, Kwon KY, Hwang IS, Roh MS & Seo JW 2012 Altered expression of microRNA miR-21, miR-155, and let-7a and their roles in pulmonary neuroendocrine tumors. Pathology International 62 583-591. (doi:10.1111/j.1440-1827.2012.02845.x)
74. Lembeck F 1954 Detection of 5-hydroxytryptamine in carcinoid metastases. Naunyn-Schmiedebergs Archiv fur experimentelle Pathologie und Pharmakologie 221 50-66.
75. Li F, Ye B, Hong L, Xu H & Fishbein MC 2011 Epigenetic modifications of histone h4 in lung neuroendocrine tumors. Applied Immunohistochemistry & Molecular Morphology 19 389-394. (doi:10.1097/PAI.0b013e3182108e2e)
76. Li SC, Martinjn C, Essaghir A, Lloyd RV, Demoulin J, Oberg K & Giandomenico V 2012 Role of microRNAs in small intestinal neuroendocrine tumours. Neuroendocrinology 96 1-72.
77. Lister R, O'Malley RC, Tonti-Filippini J, Gregory BD, Berry CC, Millar AH & Ecker JR 2008 Highly integrated single-base resolution maps of the epigenome in Arabidopsis. Cell 133 523-536. (doi:10.1016/j.cell.2008.03.029)
78. Liu L, Broaddus RR, Yao JC, Xie S, White JA, Wu TT, Hamilton SR & Rashid A 2005 Epigenetic alterations in neuroendocrine tumors: methylation of RAS-association domain family 1, isoform A and p16 genes are associated with metastasis. Modern Pathology 18 1632-1640.
79. Liu R, Liao J, Yang M, Shi Y, Peng Y, Wang Y, Pan E, Guo W, Pu Y & Yin L 2012 Circulating miR-155 expression in plasma: a potential biomarker for early diagnosis of esophageal cancer in humans. Journal of Toxicology and Environmental Health. Part A 75 1154-1162. (doi:10.1080/15287394.2012.699856)
80. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA et al. 2005 MicroRNA expression profiles classify human cancers. Nature 435 834-838. (doi:10.1038/nature03702)
81. Lubomierski N, Kersting M, Bert T, Muench K, Wulbrand U, Schuermann M, Bartsch D & Simon B 2001 Tumor suppressor genes in the 9p21 gene cluster are selective targets of inactivation in neuroendocrine gastroenteropancreatic tumors. Cancer Research 61 5905-5910.
82. Magerl C, Ellinger J, Braunschweig T, Kremmer E, Koch LK, Holler T, Buttner R, Luscher B & Gutgemann I 2010 H3K4 dimethylation in hepatocellular carcinoma is rare compared with other hepatobiliary and gastrointestinal carcinomas and correlates with expression of the methylase Ash2 and the demethylase LSD1. Human Pathology 41 181-189. (doi:10.1016/j.humpath.2009.08. 007)
83. Malpeli G, Amato E, Dandrea M, Fumagalli C, Debattisti V, Boninsegna L, Pelosi G, Falconi M & Scarpa A 2011 Methylation-associated down-regulation of RASSF1A and up-regulation of RASSF1C in pancreatic endocrine tumors. BMC Cancer 11 351. (doi:10.1186/1471-2407-11-351)
84. Mann BS, Johnson JR, Cohen MH, Justice R & Pazdur R 2007 FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 12 1247-1252. (doi:10.1634/theoncologist. 12-10-1247)
85. Margetts CD, Astuti D, Gentle DC, Cooper WN, Cascon A, Catchpoole D, Robledo M, Neumann HP, Latif F & Maher ER 2005 Epigenetic analysis of HIC1, CASP8, FLIP, TSP1, DCR1, DCR2, DR4, DR5, KvDMR1, H19 and preferential 11p15.5maternal-allele loss in von Hippel-Lindau and sporadic phaeochromocytomas. Endocrine-Related Cancer 12 161-172. (doi:10.1677/erc.1. 00865)
86. Margetts CD, Morris M, Astuti D, Gentle DC, Cascon A, McRonald FE, Catchpoole D, Robledo M, Neumann HP, Latif F et al. 2008 Evaluation of a functional epigenetic approach to identify promoter region methylation in phaeochromocytoma and neuroblastoma. Endocrine-Related Cancer 15 777-786. (doi:10.1677/ERC-08-0072)
87. Matei D, Fang F, Shen C, Schilder J, Arnold A, Zeng Y, Berry WA, Huang T & Nephew KP 2012 Epigenetic resensitization to platinum in ovarian cancer. Cancer Research 72 2197-2205. (doi:10.1158/0008-5472.CAN-11-3909)
88. Mei M, Deng D, Liu TH, Sang XT, Lu X, Xiang HD, Zhou J, Wu H, Yang Y, Chen J et al. 2009 Clinical implications of microsatellite instability and MLH1 gene inactivation in sporadic insulinomas. Journal of Clinical Endocrinology and Metabolism 94 3448-3457. (doi:10.1210/jc.2009-0173)
89. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB & Sidransky D 1995 50 CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nature Medicine 1 686-692. (doi:10.1038/nm0795-686)
90. Meyer-Rochow GY, Jackson NE, Conaglen JV, Whittle DE, Kunnimalaiyaan M, Chen H, Westin G, Sandgren J, Stalberg P, Khanafshar E et al. 2010 MicroRNA profiling of benign and malignant pheochromocytomas identifies novel diagnostic and therapeutic targets. Endocrine-Related Cancer 17 835-846. (doi:10.1677/ERC-10-0142)
91. Modlin IM, Shapiro MD & Kidd M 2004 Siegfried Oberndorfer: origins and perspectives of carcinoid tumors. Human Pathology 35 1440-1451. (doi:10.1016/j.humpath.2004.09.018)
92. Moertel CG, Hanley JA & Johnson LA 1980 Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced isletcell carcinoma. New England Journal of Medicine 303 1189-1194. (doi:10.1056/ NEJM198011203032101)
93. Mohammed TA, Holen KD, Jaskula-Sztul R, Mulkerin D, Lubner SJ, Schelman WR, Eickhoff J, Chen H & Loconte NK 2011 A pilot phase II study of valproic acid for treatment of low-grade neuroendocrine carcinoma. Oncologist 16 835-843. (doi:10.1634/theoncologist. 2011-0031)
94. Muller CI, Ruter B, Koeffler HP & Lubbert M 2006 DNA hypermethylation of myeloid cells, a novel therapeutic target in MDS and AML. Current Pharmaceutical Biotechnology 7 315-321. (doi:10.2174/138920106 778521523)
95. Muscarella P, Melvin WS, Fisher WE, Foor J, Ellison EC, Herman JG, Schirmer WJ, Hitchcock CL, DeYoung BR & Weghorst CM 1998 Genetic alterations in gastrinomas and nonfunctioning pancreatic neuroendocrine tumors: an analysis of p16/MTS1 tumor suppressor gene inactivation. Cancer Research 58 237-240.
96. Oberg K, Funa K & Alm G 1983 Effects of leukocyte interferon on clinical symptoms and hormone levels in patients with mid-gut carcinoid tumors and carcinoid syndrome. New England Journal of Medicine 309 129-133. (doi:10.1056/NEJM198307213090301)
97. O'Connor DT & Deftos LJ 1986 Secretion of chromogranin A by peptideproducing endocrine neoplasms. New England Journal of Medicine 314 1145-1151. (doi:10.1056/NEJM198605013141803)
98. Okano M, Xie S & Li E 1998a Cloning and characterization of a family of novel mammalian DNA (cytosine-5) methyltransferases. Nature Genetics 19 219-220. (doi:10.1038/890)
99. Okano M, Xie S & Li E 1998b Dnmt2 is not required for de novo and maintenancemethylation of viral DNA in embryonic stem cells. Nucleic Acids Research 26 2536-2540. (doi:10.1093/nar/26.11.2536)
100. Okano M, Bell DW, Haber DA & Li E 1999 DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 99 247-257. (doi:10.1016/S0092-8674(00)81656-6)
101. Oki Y, Aoki E & Issa JP 2007 Decitabine - bedside to bench. Critical Reviews in Oncology/Hematology 61 140-152. (doi:10.1016/j.critrevonc. 2006.07.010)
102. Ozata DM, Caramuta S, Velazquez-Fernandez D, Akcakaya P, Xie H, Hoog A, Zedenius J, Backdahl M, Larsson C & Lui WO 2011 The role of microRNA deregulation in the pathogenesis of adrenocortical carcinoma. Endocrine-Related Cancer 18 643-655. (doi:10.1530/ERC-11-0082)
103. Patterson EE, Holloway AK, Weng J, Fojo T & Kebebew E 2011 MicroRNA profiling of adrenocortical tumors reveals miR-483 as a marker of malignancy. Cancer 117 1630-1639. (doi:10.1002/cncr.25724)
104. Patterson E, Webb R, Weisbrod A, Bian B, He M, Zhang L, Holloway AK, Krishna R, Nilubol N, Pacak K et al. 2012 The microRNA expression changes associated with malignancy and SDHB mutation in pheochromocytoma. Endocrine-Related Cancer 19 157-166. (doi:10.1530/ERC-11-0308)
105. Pelosi G, Fumagalli C, Trubia M, Sonzogni A, Rekhtman N, Maisonneuve P, Galetta D, Spaggiari L, Veronesi G, Scarpa A et al. 2010 Dual role of RASSF1 as a tumor suppressor and an oncogene in neuroendocrine tumors of the lung. Anticancer Research 30 4269-4281.
106. Pernow B & Waldenstrom J 1954 Paroxysmal flushing and other symptoms caused by 5-hydroxytryptamine and histamine in patients with malignant tumours. Lancet 267 951. (doi:10.1016/S0140-6736 (54)92559-3)
107. Pizzi S, Azzoni C, Bottarelli L, Campanini N, D'Adda T, Pasquali C, Rossi G, Rindi G & Bordi C 2005 RASSF1A promoter methylation and 3p21.3 loss of heterozygosity are features of foregut, but not midgut and hindgut, malignant endocrine tumours. Journal of Pathology 206 409-416. (doi:10.1002/path.1784)
108. Radtke F & Raj K 2003 The role of Notch in tumorigenesis: oncogene or tumour suppressor? Nature Reviews. Cancer 3 756-767. (doi:10.1038/nrc1186)
109. Rahman MM, Qian ZR, Wang EL, Yoshimoto K, Nakasono M, Sultana R, Yoshida T, Hayashi T, Haba R, Ishida M et al. 2010 DNA methyltransferases 1, 3a, and 3b overexpression and clinical significance in gastroenteropancreatic neuroendocrine tumors. Human Pathology 41 1069-1078. (doi:10.1016/j.humpath. 2010.01.011)
110. Rajguru S, Lubner SJ, Mulkerin D, Schelman WR, Winterle N, Holen KD, Leverson G, Chen H & LoConte NK 2012 A phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in low-grade neuroendocrine tumors. ASCO Meeting Abstracts 30 e14554.
111. Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, Valle J, Metrakos P, Smith D, Vinik A et al. 2011 Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. New England Journal of Medicine 364 501-513. (doi:10.1056/NEJMoa1003825)
112. Rechache NS, Wang Y, Stevenson HS, Killian JK, Edelman DC, Merino M, Zhang L, Nilubol N, Stratakis CA, Meltzer PS et al. 2012 DNA methylation profiling identifies global methylation differences and markers of adrenocortical tumors. Journal of Clinical Endocrinology and Metabolism 97 E1004-E1013. (doi:10.1210/jc.2011-3298)
113. Rinke A, Muller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, Mayer C, Aminossadati B, Pape UF, Blaker M et al. 2009 Placebocontrolled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. Journal of Clinical Oncology 27 4656-4663. (doi:10.1200/JCO.2009.22.8510)
114. Roldo C, Missiaglia E, Hagan JP, Falconi M, Capelli P, Bersani S, Calin GA, Volinia S, Liu CG, Scarpa A et al. 2006 MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. Journal of Clinical Oncology 24 4677-4684. (doi:10.1200/JCO.2005.05.5194)
115. Ruebel K, Leontovich AA, Stilling GA, Zhang S, Righi A, Jin L & Lloyd RV 2010 MicroRNA expression in ileal carcinoid tumors: downregulation of microRNA-133a with tumor progression. Modern Pathology 23 367-375. (doi:10.1038/modpathol.2009.161)
116. Sakai T, Toguchida J, Ohtani N, Yandell DW, Rapaport JM & Dryja TP 1991 Allele-specific hypermethylation of the retinoblastoma tumorsuppressor gene. American Journal of Human Genetics 48 880-888.
117. Schmitt AM, Schmid S, Rudolph T, Anlauf M, Prinz C, Kloppel G, Moch H, Heitz PU, Komminoth P & Perren A 2009 VHL inactivation is an important pathway for the development of malignant sporadic pancreatic endocrine tumors. Endocrine-Related Cancer 16 1219-1227. (doi:10.1677/ERC-08-0297)
118. Schmitz KJ, Helwig J, Bertram S, Sheu SY, Suttorp AC, Seggewiss J, Willscher E, Walz MK, Worm K & Schmid KW 2011 Differential expression of microRNA-675, microRNA-139-3p and microRNA-335 in benign and malignant adrenocortical tumours. Journal of Clinical Pathology 64 529-535. (doi:10.1136/jcp.2010.085621)
119. Schwartzentruber J, Korshunov A, Liu XY, Jones DT, Pfaff E, Jacob K, Sturm D, Fontebasso AM, Quang DA, Tonjes M et al. 2012 Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 482 226-231. (doi:10.1038/nature10833)
120. Seligson DB, Horvath S, Shi T, Yu H, Tze S, Grunstein M & Kurdistani SK 2005 Global histone modification patterns predict risk of prostate cancer recurrence. Nature 435 1262-1266. (doi:10.1038/nature03672)
121. Serrano J, Goebel SU, Peghini PL, Lubensky IA, Gibril F & Jensen RT 2000 Alterations in the p16INK4a/CDKN2A tumor suppressor gene in gastrinomas. Journal of Clinical Endocrinology and Metabolism 85 4146-4156. (doi:10.1210/jc.85.11.4146)
122. Shah MH, Binkley P, Chan K, Xiao J, Arbogast D, Collamore M, Farra Y, Young D & Grever M 2006 Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors. Clinical Cancer Research 12 3997-4003. (doi:10.1158/1078-0432.CCR-05-2689)
123. Shivakumar L, Minna J, Sakamaki T, Pestell R & White MA 2002 The RASSF1A tumor suppressor blocks cell cycle progression and inhibits cyclin D1 accumulation. Molecular and Cellular Biology 22 4309-4318. (doi:10.1128/MCB.22. 12.4309-4318.2002)
124. Singh P, Soon PS, Feige JJ, Chabre O, Zhao JT, Cherradi N, Lalli E & Sidhu SB 2012 Dysregulation of microRNAs in adrenocortical tumors. Molecular and Cellular Endocrinology 351 118-128. (doi:10.1016/j.mce. 2011.09.041)
125. Soon PS, Tacon LJ, Gill AJ, Bambach CP, Sywak MS, Campbell PR, Yeh MW, Wong SG, Clifton-Bligh RJ, Robinson BG et al. 2009 miR-195 and miREndocrine-483-5p identified as predictors of poor prognosis in adrenocortical cancer. Clinical Cancer Research 15 7684-7692. (doi:10.1158/1078-0432.CCR-09- 1587)
126. Stricker I, Tzivras D, Nambiar S, Wulf J, Liffers ST, Vogt M, Verdoodt B, Tannapfel A & Mirmohammadsadegh A 2012 Site- and grade-specific diversity of LINE1 methylation pattern in gastroenteropancreatic neuroendocrine tumours. Anticancer Research 32 3699-3706.
127. Suh I, Weng J, Fernandez-Ranvier G, Shen WT, Duh QY, Clark OH & Kebebew E 2010 Antineoplastic effects of decitabine, an inhibitor of DNA promoter methylation, in adrenocortical carcinoma cells. Archives of Surgery 145 226-232. (doi:10.1001/archsurg.2009.292)
128. Tahiliani M, Koh KP, Shen Y, Pastor WA, Bandukwala H, Brudno Y, Agarwal S, Iyer LM, Liu DR, Aravind L et al. 2009 Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 324 930-935. (doi:10.1126/science.1170116)
129. The American Association for Cancer Research Human Epigenome Task Force & European Union NoE, Scientific Advisory Board 2008 Moving AHEAD with an international human epigenome project. Nature 454 711-715. (doi:10.1038/454711a)
130. Tombol Z, Szabo PM, Molnar V, Wiener Z, Tolgyesi G, Horanyi J, Riesz P, Reismann P, Patocs A, Liko I et al. 2009 Integrative molecular bioinformatics study of human adrenocortical tumors: microRNA, tissue-specific target prediction, and pathway analysis. Endocrine-Related Cancer 16 895-906. (doi:10.1677/ERC-09-0096)
131. Tombol Z, Eder K, Kovacs A, Szabo PM, Kulka J, Liko I, Zalatnai A, Racz G, Toth M, Patocs A et al. 2010 MicroRNA expression profiling in benign (sporadic and hereditary) and recurring adrenal pheochromocytomas. Modern Pathology 23 1583-1595. (doi:10.1038/modpathol.2010.164)
132. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB & Issa JP 1999 CpG island methylator phenotype in colorectal cancer. PNAS 96 8681-8686. (doi:10.1073/pnas.96.15.8681)
133. Ulaner GA, Huang HY, Otero J, Zhao Z, Ben-Porat L, Satagopan JM, Gorlick R, Meyers P, Healey JH, Huvos AG et al. 2003 Absence of a telomere maintenance mechanism as a favorable prognostic factor in patients with osteosarcoma. Cancer Research 63 1759-1763.
134. Waddington CH 1957 The Strategy of the Genes: a Discussion of Some Aspects of Theoretical Biology. London: Allen, Unwin.
135. Wang T, Lv M, Shen S, Zhou S, Wang P, Chen Y, Liu B, Yu L & Hou Y 2012 Cell-free microRNA expression profiles in malignant effusion associated with patient survival in non-small cell lung cancer. PLoS ONE 7 e43268. (doi:10.1371/journal.pone.0043268)
136. Warneboldt J, Haller F, Horstmann O, Danner BC, Fuzesi L, Doenecke D & Happel N 2008 Histone H1x is highly expressed in human neuroendocrine cells and tumours. BMC Cancer 8 388. (doi:10.1186/1471-2407-8-388)
137. Wild A, Ramaswamy A, Langer P, Celik I, Fendrich V, Chaloupka B, Simon B & Bartsch DK 2003 Frequent methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene in pancreatic endocrine tumors. Journal of Clinical Endocrinology and Metabolism 88 1367-1373. (doi:10.1210/jc.2002- 021027)
138. de Wilde RF, Heaphy CM, Maitra A, Meeker AK, Edil BH, Wolfgang CL, Ellison TA, Schulick RD, Molenaar IQ, Valk GD et al. 2012 Loss of ATRX or DAXX expression and concomitant acquisition of the alternative lengthening of telomeres phenotype are late events in a small subset of MEN-1 syndrome pancreatic neuroendocrine tumors. Modern Pathology 25 1033-1039.
139. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG et al. 2011 Everolimus for advanced pancreatic neuroendocrine tumors. New England Journal of Medicine 364 514-523. (doi:10.1056/NEJMoa1009290)
140. Yashiro T, Fulton N, Hara H, Yasuda K, Montag A, Yashiro N, Straus F, II, Ito K, Aiyoshi Y & Kaplan EL 1993 Comparison of mutations of ras oncogene in human pancreatic exocrine and endocrine tumors. Surgery 114 758-763 (discussion 763-754).
141. Yoshimoto K, Iwahana H, Fukuda A, Sano T, Saito S & Itakura M 1992 Role of p53 mutations in endocrine tumorigenesis: mutation detection by polymerase chain reaction-single strand conformation polymorphism. Cancer Research 52 5061-5064.
142. Zhang HY, Rumilla KM, Jin L, Nakamura N, Stilling GA, Ruebel KH, Hobday TJ, Erlichman C, Erickson LA & Lloyd RV 2006 Association of DNA methylation and epigenetic inactivation of RASSF1A and β-catenin with metastasis in small bowel carcinoid tumors. Endocrine 30 299-306. (doi:10.1007/s12020-006- 0008-1)